Showing 9381-9390 of 19228 results for "".
- Beta-lactam Antibiotics and Infant Gut Microbiota: Clinical Implications of Altered Diversityhttps://reachmd.com/news/beta-lactam-antibiotics-and-infant-gut-microbiota-clinical-implications-of-altered-diversity/2484821/Early systemic beta-lactam exposure in term infants was linked to lower gut microbial alpha diversity and selective loss of key commensals that support metabolic and immune development. Antibiotics remain a common response to suspected or confirmed bacterial infectio
- Combined Ianalumab and Eltrombopag Therapy in Immune Thrombocytopenia: Insights from the VAYHIT2 Trialhttps://reachmd.com/news/combined-ianalumab-and-eltrombopag-therapy-in-immune-thrombocytopenia-insights-from-the-vayhit2-trial/2484822/VAYHIT2: Ianalumab plus eltrombopag extends response durability in previously treated p
- Systematic Review Shows BTX Effective for Ischemic Digital Complicationshttps://reachmd.com/news/systematic-review-btx-effective-for-ischemic-digital-complications/2484841/Botulinum toxin (BTX) injections may offer a promising rescue therapy for patients with refractory digital ischemia, ulcers, or gangrene associated with systemic sclerosis and other vasculopathies, according to findings from a systematic review in
- Advancements in Pretargeted Imaging: Enhancing Tumor Contrast Through Bioorthogonal Chemistryhttps://reachmd.com/news/advancements-in-pretargeted-imaging-enhancing-tumor-contrast-through-bioorthogonal-chemistry/2484824/DZ-Lys-TCO paired with 68Ga-DOTA-H-Tz markedly improves tumor contrast and reduces off-target exposure in preclinical PET/NIRF models—sharpening lesion delineation while lowering systemic radionuclide burden through staged delivery of the targeting vector and radioligand.</
- FDA Regulatory Moves and Their Impact on Urologic Therapeautics: A Case of Detalimogenehttps://reachmd.com/news/fda-regulatory-moves-and-their-impact-on-urologic-therapeautics-a-case-of-detalimogene/2484820/The FDA selected detalimogene for its Manufacturing Readiness Program, advancing regulatory alignment for this non
- Real-World Study Confirms Ixekizumab Outperforms Ustekinumab in Psoriasishttps://reachmd.com/news/real-world-study-confirms-ixekizumab-outperforms-ustekinumab-in-psoriasis/2484790/A recent real-world studyreplicated the results of the IXORA-S trial, which demonstrated the efficacy of ixekizumab over ustekinumab for treating moderate-to-severe plaque psoriasis. Researchers for the observational analysis, c
- Guideline-Driven Recommendations for Pediatric Renal Imaging: Insights from the European Society of Paediatric Radiologyhttps://reachmd.com/news/guideline-driven-recommendations-for-pediatric-renal-imaging-insights-from-the-european-society-of-paediatric-radiology/2484786/The European Society of Pediatric Radiology guideline now endorses an ultrasound‑first strategy for pediatric renal imaging, shiftin
- Optimizing Airway Management in Cardiac Arrest: Key Insights from a Cadaver Studyhttps://reachmd.com/news/optimizing-airway-management-in-cardiac-arrest-key-insights-from-a-cadaver-study/2484779/A cadaver study found that airway device choice produced measurable differences in intra-arrest ventilation; tracheal intubation yie
- Understanding Low Anterior Resection Syndrome (LARS) in Rectal Surgery: Prevalence, Risk Factors, and Implications for Surgical Practicehttps://reachmd.com/news/understanding-low-anterior-resection-syndrome-lars-in-rectal-surgery-prevalence-risk-factors-and-implications-for-surgical-practice/2484784/Low Anterior Resection Syndrome (LARS) is a common, high‑impact complication after sphincter‑preserving rectal resection that substantially reduces postoperative quality of life.
- Real-World Insights: Switching from Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuriahttps://reachmd.com/news/real-world-insights-switching-from-eculizumab-to-ravulizumab-in-paroxysmal-nocturnal-hemoglobinuria/2484745/Switching adults with PNH from eculizumab to ravulizumab preserved biochemical and clinical disease control while substantially extending dosing intervals, according to